ArticleAnnals of surgical oncology2026
Association Between Tumor Size and Nodal Positivity for HER2+ and Triple-Negative Early-Stage Breast Cancer: A Population-Based Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 2021 American Society of Clinical Oncology (ASCO) guidelines recommend neoadjuvant systemic therapy (NST) over upfront surgery for human epidermal growth factor receptor 2-positive (HER2+) and triple-negative breast cancers if node-positive or at least T1c. In practice, many clinicians use a 2-cm (T2) or node-positive threshold for NST, leaving controversy regarding management of clinically node-negative T1c HER2+ and triple-negative tumors. Accurate estimation of nodal status is therefore essential to guide management. This study evaluated the association between tumor size and nodal involvement in T1-T2 HER2+ and triple-negative tumors and assessed predictors of nodal positivity in T1c tumors.
methodsA population-based retrospective cohort study was conducted using Institute for Clinical Evaluative Sciences (ICES) Ontario administrative data (2000-2019). The primary outcome was regional nodal positivity (N1-N3) stratified by tumor size (T1a-T2) and receptor subtype. Multivariable logistic regression identified independent predictors of nodal positivity in T1c tumors.
resultsThe study analyzed 11,007 T1a-T2 cases including 1923 hormone receptor-negative (HR-)-HER2+ cases, 4542 HR+HER2+ cases, and 4542 triple-negative cases. Among T1a/b tumors, the nodal positivity rates ranged from 11 to 22% for HR-HER2+, 11-14% for HR+HER2+, and 7-11% for triple-negative tumors. Among T1c tumors, the rates were 32% for HR-HER2+, 26% for HR+HER2+, and 19% for triple-negative tumors. Among T2 tumors, the rates were 38% for HR-HER2+, 42% for HR+HER2+, and 30% for triple-negative tumors. Among T1c tumors, HR-HER2+ subtype and patient age younger than 50 years were independently associated with increased odds of nodal positivity.
conclusionsNodal positivity rates are substantial for T1-T2 HER2+ and triple-negative tumors, even for T1a/b tumors. Among T1c tumors, HR-HER2+ subtype and age of 50 years or younger independently predicted increased nodal positivity, supporting NST especially for these patients.
Indexed as
Identifiers
42002711What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.